



Published in final edited form as:

Org Biomol Chem. 2010 June 21; 8(12): 2719–2727. doi:10.1039/c001036g.

A panel of subunit-selective activity-based proteasome probes[‡]

Martijn Verdoes^{a,§}, Lianne I. Willems^a, Wouter A. van der Linden^a, Boudewijn A. Duivenvoorden^a, Gijsbert A. van der Marel^a, Bogdan I. Florea^a, Alexei F. Kisselev^b, and Herman S. Overkleeft^c

^a Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, PO Box 9502, 2300 RA Leiden, The Netherlands ^b Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, 1 Medical Center Drive, HB7936, Lebanon, NH 03756, USA, Alexei.F.Kisselev@Dartmouth.edu ^c Leiden Institute of Chemistry and Netherlands Proteomics Centre, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC Leiden, The Netherlands, h.s.overkleeft@chem.leidenuniv.nl

Abstract

Mammals express seven different catalytically active proteasome subunits. In order to determine the roles of the different proteolytically active subunits in antigen presentation and other cellular processes, highly specific inhibitors and activity-based probes that selectively target specific active sites are needed. In this work we present the development of fluorescent activity-based probes that selectively target the $\beta 1$ and $\beta 5$ sites of the constitutive proteasome.

Introduction

Proteasomes degrade the majority of proteins in mammalian cells and are established targets for the development of anticancer drugs. All eukaryotic proteasomes have three types of active sites. The site located on the $\beta 1$ subunit is referred to as caspase-like, the site on subunit $\beta 2$ as trypsin-like and the site on the $\beta 5$ subunit as chymotrypsin-like, although the subunits are rather more promiscuous in their substrate preference than is suggested by this designation. Four additional proteolytically active sites are present on proteasomes in specific cell types in vertebrates. In cells of the immune system, the $\beta 1i$, $\beta 2i$ and the $\beta 5i$ subunits replace the corresponding constitutive subunits in newly formed proteasome particles called immunoproteasomes.¹ Cortical thymic epithelial cells express an additional proteolytic subunit, the $\beta 5t$, which replaces $\beta 5i$ in immunoproteasomes to form the thymoproteasome.²

This diversity of active sites in eukaryotic proteasomes is in a stark contrast to the much simpler proteasomes in bacteria and archaea, which possess only one or two types of active sites. In prokaryotic proteasomes there are proteolytic active sites on all 14 β -subunits. The total number of active sites on eukaryotic proteasomes is 6 (two of each type). The reasons for such dramatic reduction in total number of active sites (14 to 6) in favor of more diverse specificity are not clear. Site-directed mutagenesis in yeast revealed that the different active sites play specific roles in protein degradation, and that their contribution to growth, viability and stress resistance of yeast strains are strikingly different.³ According to these

[‡]Electronic supplementary information (ESI) available: ¹H NMR spectra. See DOI: 10.1039/c001036g

Correspondence to: Alexei F. Kisselev; Herman S. Overkleeft.

[§]Present address: Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA

studies, the $\beta 5$ sites are the most important, whereas the $\beta 1$ sites are apparently redundant. Thus, it is not clear why $\beta 1$ sites are present in all eukaryotes from yeast to humans.

The proteasome inhibitor bortezomib (Velcade, PS-341)⁴ is being used for the treatment of multiple myeloma⁵ and mantle cell lymphoma,⁶ and at least three other inhibitors are tested clinically. The role of individual active sites as drug targets in cancer has not been fully elucidated. The $\beta 5$ and $\beta 5i$ sites are the primary targets of all inhibitors used in the clinic, but the majority of them also target other sites. For example, bortezomib also inhibits $\beta 1$ sites of the constitutive proteasome and $\beta 1i$ and $\beta 2i$ sites of the immunoproteasome.⁷⁻⁸ Whether or not the co-inhibition of $\beta 1/\beta 1i$ and $\beta 2i$ sites contributes to anti-neoplastic activity of bortezomib is not clear. Using newly developed specific inhibitors of the $\beta 1$ and $\beta 5$ sites (Fig. 1A, NC-001 (**1**) and NC-005 (**2**), respectively), we have recently demonstrated that inhibition of the $\beta 1$ sites sensitizes myeloma cells to $\beta 5$ selective inhibitors.⁹ This suggests that the $\beta 1$ sites, despite their apparent redundancy, have to be considered co-targets for anti-neoplastic drugs. Furthermore, proteasomes are involved in the generation of antigenic peptides loaded in MHC class I complexes, but the contribution of each separate active proteasome subunit to the epitope repertoire has not yet been defined, largely due to the lack of cell permeable site-specific inhibitors.

In order to determine the roles of the different proteolytically active subunits in antigen presentation and other cellular processes, highly specific inhibitors and activity-based probes that selectively target specific active sites are needed. In this study we use the inhibitors we previously reported as being selective for the $\beta 1$ and $\beta 5$ sites,⁹ Ac-Ala-Pro-Nle-LeuEK (**1**) and Napht-Tyr(OMe)-Phe-LeuEK (**2**), respectively, as the basis for the development of a panel of fluorescent site-specific activity-based probes.

Results and discussion

The majority of proteasome inhibitors are short peptides with an electrophilic group at the C-terminus.¹⁰ This electrophilic “warhead” reacts with the proteasome’s catalytic N-terminal threonines. Previously, we demonstrated that swapping the peptide portions and warheads of known proteasome inhibitors can alter active site specificities and potencies.¹¹ We decided to test whether changing the warheads on compounds **1** and **2** improves their potency and specificity. The best characterized and most commonly used proteasome warheads are aldehydes, vinyl sulfones, boronates and epoxyketones. Of these, only vinyl sulfones and epoxyketones are suitable for use in activity-based probes, since only these form covalent irreversible bonds with the proteasome active sites that are not destroyed during heating under denaturing conditions, a mandatory step preceding analysis of probe-treated samples by SDS-PAGE. Therefore, we have synthesized derivatives of **1** and **2** armed with leucine phenol vinyl sulfone (LeuVS-PhOH),¹² leucine methyl vinyl sulfone (LeuVS)¹³ and leucine epoxyketone (LeuEK)¹⁴ to arrive at a panel of 6 potential subunit specific proteasome inhibitors (Fig. 1B). All inhibitors used in the study were synthesized by coupling the recognition fragments to the leucine-derived warheads. In order to avoid epimerization at the P2 position, we used the azide coupling (Scheme 1). Hence, the synthesis commenced with the preparation of the hydrazides of the peptidic recognition elements. Fmoc-based solid phase peptide synthesis using HMPB-functionalized MBHA resin gave immobilized acetyl capped tripeptide **3**. After mild acidic cleavage from resin, the crude peptide was treated with TMS-diazomethane to give methyl ester **5**. Refluxing in methanol in the presence of an excess of hydrazine resulted in the $\beta 1$ recognition element peptide hydrazide **6**. The $\beta 5$ recognition peptide hydrazide was prepared by condensation of Boc-protected tyrosine methyl ether **7** with phenylalanine methyl ester to give dipeptide **8**. After acidic cleavage of the Boc protective group and capping with 2-(naphthalen-2-yl)-acetic acid, methyl ester **9** was reacted with hydrazine in refluxing methanol to give peptide

hydrazide **10**. The recognition element peptide hydrazides were treated with *tert*-butyl nitrite under acidic conditions to generate an acyl azide *in situ*. After addition of base, the warhead amines (synthesized according to literature procedures^{12–14}) were reacted with the activated peptides to give the hybrid structures **Ia–c** and **IIa–c**.

The proteasome inhibition profile of the panel of 6 modified oligopeptides was determined in competition experiments *versus* the fluorescent broad-spectrum activity-based proteasome probe MV151.15 Human Embryonic Kidney (HEK293T) cell lysates expressing the constitutive proteasome were exposed to increasing concentrations of the inhibitors for one hour. Residual proteasome activity was labeled with MV151, after which the proteins were denatured, separated on SDS-PAGE and visualized using a fluorescence scanner (Fig. 2A). Apparent IC₅₀ values were determined by quantification of the fluorescent gel bands (Fig. 2A and Table 1). As reported, inhibitors **Ia** and **Ic** (**1**)⁹ selectively block the β 1 subunit. The selectivity and potency of the methyl vinyl sulfone-equipped β 1 recognition peptide **Ib** is in the same order of magnitude as the phenol vinyl sulfone **Ia**, but both are one order of magnitude less potent than the β 1 selective epoxyketone **Ic**.

In the panel of inhibitors containing the β 5 recognition element, phenol vinyl sulfone **IIa** is a more selective inhibitor of the β 5 subunit than the parent epoxyketone **IIc** (**2**), but still targets β 1 and β 2 at higher concentrations. However, vinyl sulfone **IIb** is a very potent and very selective inhibitor for the β 5 subunit (Fig. 2B). Although about 10 times more potent for β 5, the parent epoxyketone **IIc** (**2**) was much less selective, since it also blocks the β 2 subunit, leaving β 1 as the sole active proteasome subunit (Fig. 2C).

Three inhibitors were chosen as starting points for the development of fluorescent activity-based probes: **Ic** that is selective for β 1, **IIb** as a selective and potent inhibitor for β 5 and **IIc** inhibiting β 2 and β 5. It was reasoned that replacing the aromatic naphthyl acetic acid in inhibitors **IIb** and **IIc** (**2**) by azido-BODIPY¹⁷ would not affect the specificity of the resulting fluorescent probes. The synthesis of the β 5 targeted probes commenced with the transformation of the Boc-protected dipeptide methyl ester **8** into the corresponding hydrazide **11** (Scheme 2). Azide coupling with LeuVS gave methyl vinyl sulfone **12**. Acidic deprotection and subsequent capping of the free amine with azido-BODIPY-OSu (**13**) gave the fluorescent probe **14**. Similarly, β 2/ β 5 targeting probe **16** was constructed from Boc-protected tripeptide epoxyketone **15**.

For the synthesis of a fluorescent β 1 selective probe, we took advantage of the previously described green fluorescent acetylene functionalized BODIPY dye **22**.¹⁸ The azide equipped intermediate **21** is easily accessible by replacing the acetyl in **Ic** with an azido glycine. Standard solid-phase peptide synthesis and subsequent capping with azido glycine afforded resin **17** (Scheme 3). Mild acidic cleavage, followed by reaction with TMS–diazomethane resulted in azido containing peptide methyl ester **19**, which was converted to the corresponding hydrazide (**20**). An azide coupling with the LeuEK warhead resulted in the β 1 selective two-step activity-based proteasome probe **21**.⁹ Reaction with BODIPY dye **22** by a copper catalysed Huisgen [2 + 3] cycloaddition then afforded the fluorescently labeled probe **23** (Scheme 3).

Having synthesized the fluorescent derivatives of the subunit selective inhibitors, their proteasome labeling profile and cell-permeability were determined (Fig. 3). Fluorescently tagged epoxomicin analogues **24**¹⁸ and **25**¹⁹ (Fig. 3D), which label all proteolytically active proteasome subunits, were used as a reference. Probe **23**, designed to specifically target the β 1 active site, indeed shows a marked preference for β 1 in HEK293T cell lysates (Fig. 3A, left panel). At higher concentrations it starts to label β 5, presumably because of the increase in steric bulk and hydrophobicity due to BODIPY addition. To attest the cell permeability,

living HEK293T cells were exposed to increasing concentrations of the probe (Fig. 3B, left panel). The fact that a similar labeling profile is observed shows that the introduction of the BODIPY dye has no dramatic effect on the cell permeability of the probe. Plotting of the fluorescent band intensity gave an apparent EC_{50} value of 62 ± 5 nM for $\beta 1$ labeling (Fig. 3C, left panel). When using 1 μ M probe, one can selectively saturate the labeling of roughly all $\beta 1$ sites, leaving most of the $\beta 5$ sites untouched.

HEK293T cell lysates incubated with azido-BODIPY methyl vinyl sulfone probe **14** showed specific $\beta 5$ labeling (Fig. 3A, middle panel), with only minimal labeling of what is presumably $\beta 1$ at high concentrations. A similar labeling profile is observed when living HEK293T cells are exposed to the fluorescent probe (Fig. 3B, middle panel). Quantification of the fluorescent labeling revealed an apparent EC_{50} value of 163 ± 5 nM (Fig. 3C, middle panel). Probe **16**, designed to target $\beta 5$ and, at higher concentrations, the $\beta 2$ site, indeed labeled both sites in lysates (Fig. 3A, right panel). In living cells $\beta 5$ labeling appears to reach a maximum around 1 μ M, after which the labeling intensity starts to decrease, whereas the labeling of the $\beta 2$ subunit keeps increasing (Fig. 3B and C, right panel). The reason for this phenomenon remains to be investigated.

Poor resolution of $\beta 5$ and $\beta 1$ subunits is often a problem in the analysis of subunit-specific inhibition and labeling on SDS-PAGE. Using the probes labeled with different fluorophores developed in this work should eliminate this problem. In order to demonstrate that this is indeed the case, we have treated extracts simultaneously with the $\beta 1$ -specific probe **23** and either of $\beta 5$ -specific probes **14** and **16** (Fig. 4). Both subunits were detected and clearly resolved with 2-color imaging.

Conclusions

Building on our expertise in developing site-specific proteasome inhibitors^{9,16} we describe here the development of fluorescent subunit-specific activity-based proteasome probes **14**, **16** and **23**. We have also made the intriguing observation that replacing the epoxyketone warhead in compound **2** for a vinyl sulfone increases the specificity of the $\beta 5$ -targeting inhibitors, with the methyl vinyl sulfone inhibitor **11b** being the most $\beta 5$ specific. An advantage of the fluorescent selective proteasome probes is the better resolution of the $\beta 1$ and $\beta 5$ subunits on the SDS-PAGE gels using 2 color imaging. The ability to chemically knock-down specific active sites and being able to validate and monitor this using the fluorescent readout will facilitate the elucidation of the roles of the individual proteasome active sites as drug targets in cancer and in other biological processes such as MHC class I antigen presentation.

Experimental

General

All reagents were commercial grade and were used as received unless indicated otherwise. Toluene (Tol.) (purum), ethyl acetate (EtOAc) (puriss.), diethyl ether (Et₂O) and light petroleum ether (PetEt) (puriss.) were obtained from Riedel-de Haën. Dichloroethane (DCE), dichloromethane (DCM), dimethyl formamide (DMF) and dioxane (Biosolve) were stored on 4 Å molecular sieves. Methanol (MeOH) and *N*-methylpyrrolidone (NMP) were obtained from Biosolve. Reactions were monitored by TLC-analysis using DC-alufoleien (Merck, Kieselgel60, F254) with detection by UV-absorption (254 nm), spraying with 20% H₂SO₄ in ethanol followed by charring at ~150 °C, by spraying with a solution of (NH₄)₆Mo₇O₂₄·4H₂O (25 g L⁻¹) and (NH₄)₄Ce(SO₄)₄·2H₂O (10 g L⁻¹) in 10% sulfuric acid followed by charring at ~150 °C, or spraying with an aqueous solution of KMnO₄ (20%) and K₂CO₃ (10%). Column chromatography was performed on Screening Di-vices

Silica gel (0.040–0.063 nm). LC/MS analysis was performed on a LCQ Advantage Max (Thermo Finnigan) equipped with a Gemini C18 column (Phenomenex). The applied buffers were A: H₂O, B: MeCN and C: 1.0% aq. TFA. HRMS were recorded on a LTQ Orbitrap (Thermo Finnigan). ¹H- and ¹³C-APT-NMR spectra were recorded on a Jeol JNM-FX-200 (200/50 MHz), Bruker DPX-300 (300/75 MHz), Bruker AV-400 (400/100 MHz) equipped with a pulsed field gradient accessory, a Bruker AV-500 (500/125 MHz) or a Bruker DMX-600 (600/150 MHz) with cryoprobe. Chemical shifts are given in ppm (δ) relative to tetramethylsilane as internal standard. Coupling constants are given in Hz. All presented ¹³C-APT spectra are proton decoupled. Optical rotations were measured on a Propol automatic polarimeter (sodium D line, $\lambda = 589$ nm). Boc-LeuVS-PhOH, 12 Boc-LeuVS, 13 Boc-LeuEK14 and were synthesized as described in literature.

Ac-Ala-Pro-Nle-OMe (5)

4-Methylbenzhydrylamine (MBHA)-functionalized polystyrene resin (7.14 g, 0.7 mmol g⁻¹, 5 mmol) was washed with NMP (3 \times) followed by addition of a preactivated mixture of 4-(4-hydroxymethyl-3-methoxyphenoxy)-butyric acid (HMPB) linker (3.6 g, 15.0 mmol, 3 equiv.), BOP (6.6 g, 15 mmol, 3 equiv.) and DiPEA (5 mL, 30 mmol, 6 equiv.) in NMP. After 2 h of shaking, the resin was washed with NMP (3 \times) and DCM (3 \times), dried and used as such. Part of the resin (2 mmol) was transferred to a flask, coevaporated with DCE (2 \times), and condensed with Fmoc-Nle-OH (2.12 g, 6 mmol, 3 equiv.) under the influence of DIC (1.0 mL, 6.6 mmol, 3.3 equiv.) and DMAP (6.6 mg, 0.3 mmol, 5 mol%) in DCM for 2 h. The resin was filtered and washed with DCM (2 \times), followed by a second condensation cycle. The loading of the resin was determined to be 0.46 mmol g⁻¹ (4.28 g, 1.97 mmol, 98%) by spectrophotometric analysis. The obtained resin was submitted to two cycles of Fmoc solid-phase synthesis with Fmoc-Pro-OH and Fmoc-Ala-OH, respectively, as follows: (a) deprotection with piperidine–NMP (1: 4, v/v, 20 min.), (b) wash with NMP (3 \times), (c) coupling of Fmoc amino acid (5 mmol, 2.5 equiv.) in the presence of BOP (2.2 g, 5 mmol, 2.5 equiv.) and DiPEA (0.99 ml, 6 mmol, 3 equiv.) in NMP and shaken for at least 2 h, (d) wash with NMP (3 \times) and DCM (3 \times), yielding resin-bound Fmoc-Ala-Pro-Nle. Couplings were monitored for completion by the Kaiser test. After Fmoc deprotection of 1.2 mmol, the resin-bound tripeptide was capped with acetic anhydride (0.57 ml, 6 mmol, 5 equiv.) and DiPEA (1.98 ml, 12 mmol, 10 equiv.) for 15 min. Mild acidic cleavage of resin 3 with 1% TFA in DCM (3 \times 10 min.) resulted in Ac-Ala-Pro-Nle-OH 4 which was used without purification. The crude peptide 4 was dissolved in MeOH–Tol. (1: 1) and treated with TMS–diazomethane (1.2 ml 2 M in hexanes, 2.4 mmol, 2 equiv.) for 15 min before being coevaporated with Tol. (3 \times). Purification by flash column chromatography (DCM \rightarrow 3% MeOH in DCM) yielded the title compound as a white solid (0.36 g, 1.0 mmol, 85%). ¹H NMR (300 MHz, CDCl₃): δ ppm 7.42 (d, $J = 7.8$ Hz, 1H), 7.14 (d, $J = 7.5$ Hz, 1H), 4.78 (m, 1H), 4.64 (m, 1H), 4.50 (m, 1H), 3.78 (m, 1H), 3.74 (s, 3H), 3.59 (m, 1H), 2.29 (m, 1H), 2.12 (m, 1H), 2.06–1.93 (m, 6H), 1.80 (m, 1H), 1.66 (m, 1H), 1.36 (d, $J = 6.9$ Hz, 3H), 1.28 (m, 4H), 0.87 (t, $J = 6.8$ Hz, 3H).

Ac-Ala-Pro-Nle-hydrazide (6)

Ac-Ala-Pro-Nle-OMe (5, 0.36 g, 1.0 mmol) was dissolved in MeOH. Hydrazine monohydrate (2.9 ml, 60 mmol, 60 equiv.) was added and the reaction mixture was refluxed for 1.5 h. Tol. was added and the resulting white solid was filtered to give the title compound (0.33 g, 0.92 mmol, 92%). ¹H NMR (400 MHz, CDCl₃): δ ppm 4.60 (q, $J = 7.0$ Hz, 1H), 4.46 (dd, $J_1 = 8.2$, $J_2 = 4.6$ Hz, 1H), 4.25 (dd, $J_1 = 8.4$, $J_2 = 6.0$ Hz, 1H), 3.85–3.77 (m, 1H), 3.69–3.60 (m, 1H), 2.26–2.13 (m, 1H), 2.11–2.01 (m, 1H), 2.00–1.91 (m, 5H), 1.82–1.71 (m, 1H), 1.71–1.60 (m, 1H), 1.42–1.24 (m, 5H), 0.91 (t, $J = 6.8$ Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 174.12, 173.77, 173.45, 172.80, 61.49, 53.48, 48.50, 48.46, 32.88, 30.31, 28.97, 26.00, 23.36, 22.26, 16.88, 14.28.

Boc-Tyr(Me)-Phe-OMe (8)

HCl-H-Phe-OMe (2.16 g, 10 mmol) and Boc-Tyr(Me)-OH (**7**, 2.95 g, 10 mmol, 1 equiv.) were dissolved in DCM. BOP (4.42 g, 10 mmol, 1 equiv.) and DiPEA (3.64 ml, 16.5 mmol, 2.2 equiv.) were added and the reaction mixture was stirred for 15 h before being washed with 0.5 M HCl (aq.) and sat. aq. NaHCO₃, separated and dried over MgSO₄. Purification by flash column chromatography (20% EtOAc in PetEt → 40% EtOAc in PetEt) yielded the title compound as a white solid (4.6 g, 10 mmol, quant.). ¹H NMR (200 MHz, CDCl₃): δ ppm 7.32–7.17 (m, 4H), 7.15–7.05 (m, 3H), 7.04–6.94 (m, 2H), 6.81 (d, *J* = 8.7 Hz, 2H), 6.38 (d, *J* = 7.8 Hz, 1H), 4.78 (q, *J* = 5.9, 5.9, 5.9 Hz, 1H), 4.38–4.19 (m, 1H), 3.78 (s, 3H), 3.67 (s, 3H), 3.05 (dd, *J* = 5.9, 1.6 Hz, 2H), 2.96 (d, *J* = 6.7 Hz, 2H), 1.40 (s, 9H). ¹³C NMR (50 MHz, CDCl₃): δ ppm 171.40, 158.15, 155.30, 135.62, 129.98, 128.86, 128.31, 128.10, 126.64, 113.54, 78.93, 55.41, 54.77, 53.13, 51.80, 37.46, 37.15, 27.78.

(Tyr(Me)-Phe-OMe)-2-(naphthalen-2-yl)-acetamide (9)

Boc-Tyr(Me)-Phe-OMe (**8**, 4.6 g, 10 mmol) was dissolved in TFA–DCM 1: 1 (v/v). The reaction mixture was stirred for 15 min before being co-evaporated with Tol. (3×). The crude TFA salt was dissolved in DCM and 2-(naphthalen-2-yl)-acetic acid (1.86 g, 10 mmol, 1 equiv.), BOP (4.42 g, 10 mmol, 1 equiv.) and DiPEA (5.46 ml, 33 mmol, 3.3 equiv.) were added. After being stirred for 15 h the reaction mixture was washed with 0.5 M HCl (aq.) and sat. aq. NaHCO₃, separated and dried over MgSO₄. Purification by flash column chromatography (PetEt → EtOAc, followed by a second column: DCM → 30% EtOAc in DCM), washing with H₂O (3×) and drying over MgSO₄ gave the pure title compound as a white solid (3.55 g, 6.8 mmol, 68%). ¹H NMR (200 MHz, CDCl₃): δ ppm 8.53 (d, *J* = 7.5 Hz, 1H), 8.27 (d, *J* = 8.7 Hz, 1H), 7.91–7.70 (m, 3H), 7.59 (s, 1H), 7.54–7.40 (m, 2H), 7.32–7.16 (m, 6H), 7.11 (d, *J* = 8.7 Hz, 2H), 6.71 (d, *J* = 8.7 Hz, 2H), 4.62–4.41 (m, 2H), 3.65 (s, 3H), 3.62 (d, *J* = 13.7 Hz, 1H), 3.58 (s, 3H), 3.49 (d, *J* = 14.0 Hz, 1H), 3.13–2.83 (m, 3H), 2.67 (dd, *J*₁ = 13.7, *J*₂ = 9.9 Hz, 1H).

(Tyr(Me)-Phe-hydrazinyl)-2-(naphthalen-2-yl)-acetamide (10)

To a solution of (Tyr(Me)-Phe-OMe)-2-(naphthalen-2-yl)-acetamide (**9**, 0.52 g, 1 mmol) in MeOH was added hydrazine monohydrate (2.91 ml, 60 mmol, 60 equiv.). The reaction mixture was refluxed for 2.5 h. The title compound precipitated as a white solid and was filtered off and washed with MeOH (0.5 g, 0.95 mmol, 95%). ¹H NMR (600 MHz, CDCl₃): δ ppm 9.22 (s, 1H), 8.25 (t, *J* = 7.9, 7.9 Hz, 2H), 7.86 (d, *J* = 7.8 Hz, 1H), 7.79 (d, *J* = 7.9 Hz, 1H), 7.77 (d, *J* = 8.5 Hz, 1H), 7.62 (s, 1H), 7.50–7.44 (m, 2H), 7.29–7.21 (m, 5H), 7.20–7.15 (m, 1H), 7.10 (d, *J* = 8.6 Hz, 2H), 6.71 (d, *J* = 8.6 Hz, 2H), 4.59–4.51 (m, 2H), 4.29 (s, 2H), 3.65 (s, 3H), 3.64 (d, *J* = 12.5 Hz, 1H), 3.53 (d, *J* = 14.0 Hz, 1H), 2.99 (dd, *J*₁ = 13.7, *J*₂ = 5.6 Hz, 1H), 2.94 (dd, *J*₁ = 13.7, *J*₂ = 3.9 Hz, 1H), 2.86 (dd, *J*₁ = 13.7, *J*₂ = 8.7 Hz, 1H), 2.70 (dd, *J*₁ = 13.6, *J*₂ = 10.1 Hz, 1H). ¹³C NMR (50 MHz, CDCl₃): δ ppm 170.97, 170.00, 169.77, 157.66, 137.51, 133.91, 132.91, 131.71, 130.22, 129.50, 129.16, 128.07, 127.65, 127.41, 127.35, 127.21, 126.28, 125.93, 125.43, 113.30, 54.76, 53.98, 52.67, 42.34, 38.05, 36.70.

Synthesis of Ia–c and IIa–c; general procedure azide coupling

The peptide hydrazide was dissolved in DMF–EtOAc (1: 1, v/v) and cooled to –25 °C, before HCl (2.8 equiv., 4 M in 1,4-dioxane) and *t*BuONO (1.1 equiv.) were added. The reaction mixture was stirred for 4 h at –25 °C to form the corresponding acyl azide. Boc-protected Leucine derived warhead Boc-LeuVS-PhOH, ¹² Boc-LeuVS13 or Boc-LeuEK14 was dissolved in DCM–TFA (1: 1, v/v) and stirred for 30 min, before being coevaporated with Tol. (3×). The resulting warhead TFA-salt was dissolved in DMF and DiPEA (3.8 equiv.) was added, before the mixture was combined with the acyl azide mixture at –25 °C

(NOTE: make sure the pH is 8–9. If not, add more DiPEA). The reaction mixture was allowed to warm up to room temperature overnight. EtOAc and water were added and the organic layer was separated, dried over MgSO₄ and concentrated *in vacuo*. The crude product was purified by flash column chromatography.

Ac-Ala-Pro-Nle-Leu-4-hydroxyphenyl-vinylsulfone (Ia)

Following the general procedure for azide coupling, the title compound was obtained from Boc-LeuVS-PhOH (61 mg, 0.17 mmol, 1.1 equiv.) and Ac-Ala-Pro-Nle-hydrazide (**6**, 53.3 mg, 0.15 mmol). Purification by flash column chromatography (DCM → 6% MeOH in DCM) gave **Ia** as colorless oil (68.4 mg, 0.12 mmol, 77%). ¹H NMR (500 MHz, DMSO, *T* = 353 K): δ ppm 7.68 (d, *J* = 8.8 Hz, 2H), 6.92 (d, *J* = 8.8 Hz, 2H), 6.79 (dd, *J*₁ = 15.0, *J*₂ = 5.1 Hz, 1H), 6.54 (dd, *J*₁ = 15.1, *J*₂ = 1.4 Hz, 1H), 4.69–4.59 (m, 1H), 4.56 (q, *J* = 7.0 Hz, 1H), 4.38 (dd, *J*₁ = 8.2, *J*₂ = 5.1 Hz, 1H), 4.17 (dd, *J*₁ = 8.2, *J*₂ = 6.0 Hz, 1H), 3.84–3.73 (m, 1H), 3.68–3.56 (m, 1H), 2.26–2.09 (m, 1H), 2.07–1.84 (m, 6H), 1.81–1.59 (m, 3H), 1.58–1.49 (m, 1H), 1.47–1.38 (m, 1H), 1.36–1.24 (m, 7H), 0.97–0.83 (m, 9H). HRMS: calcd. for [C₂₉H₄₄N₄O₇SH]⁺ 593.30035, found 593.30046.

Ac-Ala-Pro-NLe-Leu-methyl-vinylsulfone (Ib)

Following the general procedure for azide coupling, the title compound was obtained from Boc-LeuVS (50.7 mg, 0.17 mmol, 1.1 equiv.) and Ac-Ala-Pro-NLe-hydrazide (**6**, 53.3 mg, 0.15 mmol). Purification by flash column chromatography (DCM → 4% MeOH in DCM) gave **Ib** as white solid (26.1 mg, 51 μmol, 34%). ¹H NMR (500 MHz, DMSO, *T* = 353 K): δ ppm 7.84 (s, 1H), 7.63–7.53 (m, 2H), 6.74–6.58 (m, 2H), 4.63–4.48 (m, 2H), 4.39–4.31 (m, 1H), 4.16 (dd, *J*₁ = 13.5, *J*₂ = 7.7 Hz, 1H), 3.69–3.61 (m, 1H), 3.60–3.52 (m, 1H), 2.95 (s, 3H), 2.10–2.00 (m, 1H), 1.98–1.86 (m, 3H), 1.84 (s, 3H), 1.77–1.67 (m, 1H), 1.67–1.55 (m, 2H), 1.54–1.46 (m, 1H), 1.45–1.35 (m, 1H), 1.33–1.24 (m, 4H), 1.22 (d, *J* = 6.8 Hz, 3H), 0.93–0.84 (m, 9H). HRMS: calcd. for [C₂₄H₄₂N₄O₆SH]⁺ 515.28978, found 515.28961.

Ac-Ala-Pro-NLe-Leu-epoxyketone (Ic)

Following the general procedure for azide coupling, the title compound was obtained from Boc-LeuEK (47.4 mg, 0.17 mmol, 1.1 equiv.) and Ac-Ala-Pro-NLe-hydrazide (**6**, 53.3 mg, 0.15 mmol). Purification by flash column chromatography (DCM → 4% MeOH in DCM) gave **Ic** as colorless oil (47.1 mg, 95 μmol, 63%). ¹H NMR (500 MHz, DMSO, *T* = 353 K): δ ppm 7.80 (s, 1H), 7.73 (d, *J* = 7.3 Hz, 1H), 7.50 (d, *J* = 5.6 Hz, 1H), 4.60–4.48 (m, 1H), 4.47–4.41 (m, 1H), 4.41–4.36 (m, 1H), 4.22 (dd, *J*₁ = 13.6, *J*₂ = 7.9 Hz, 1H), 3.72–3.59 (m, 1H), 3.57–3.47 (m, 1H), 3.18 (d, *J* = 5.2 Hz, 1H), 2.96 (d, *J* = 5.2 Hz, 1H), 2.08–1.95 (m, 1H), 1.95–1.86 (m, 2H), 1.83 (s, 3H), 1.73–1.61 (m, 2H), 1.56–1.46 (m, 1H), 1.42 (s, 3H), 1.41–1.31 (m, 2H), 1.30–1.23 (m, 4H), 1.20 (d, *J* = 6.7 Hz, 3H), 0.91 (d, *J* = 6.64 Hz, 1H), 0.88–0.83 (m, 6H). HRMS: calcd. for [C₂₅H₄₂N₄O₆H]⁺ 495.31771, found 495.31755.

(Tyr(Me)-Phe-Leu-4-hydroxyphenyl-vinylsulfone)-2-(naphthalen-2-yl)-acetamide (IIa)

Following the general procedure for azide coupling, the title compound was obtained from Boc-LeuVS-PhOH (61 mg, 0.17 mmol, 1.1 equiv.) and (Tyr(Me)-Phe-hydrazinyl)-2-(naphthalen-2-yl)-acetamide (**10**, 78.7 mg, 0.15 mmol). Crystallization from EtOAc with PetEt gave **IIa** as a white solid (88.1 mg, 0.12 mmol, 77%). ¹H NMR (400 MHz, DMSO): δ ppm 10.64 (s, 1H), 8.29 (d, *J* = 8.0 Hz, 1H), 8.25 (d, *J* = 8.4 Hz, 1H), 8.06 (d, *J* = 8.4 Hz, 1H), 7.85 (d, *J* = 7.0 Hz, 1H), 7.80–7.72 (m, 2H), 7.62 (d, *J* = 8.7 Hz, 2H), 7.58 (s, 1H), 7.50–7.42 (m, 2H), 7.25–7.20 (m, 1H), 7.18–7.13 (m, 5H), 7.07 (d, *J* = 8.6 Hz, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.71–6.61 (m, 3H), 6.22 (dd, *J*₁ = 15.1, *J*₂ = 1.3 Hz, 1H), 4.58–4.42 (m, 3H), 3.64 (s, 3H), 3.59 (d, *J* = 13.9 Hz, 1H), 3.48 (d, *J* = 13.9 Hz, 1H), 2.98–2.75 (m, 3H), 2.64 (dd, *J*₁ = 13.7, *J*₂ = 10.0 Hz, 1H), 1.62–1.50 (m, 1H), 1.39–1.25 (m, 2H), 0.81 (dd, *J*₁ =

12.6, $J_2 = 6.6$ Hz, 6H). ^{13}C NMR (100 MHz, DMSO): δ ppm 170.99, 170.17, 169.71, 161.95, 157.58, 145.37, 137.14, 133.85, 132.81, 131.61, 130.10, 129.96, 129.85, 129.61, 129.39, 128.96, 127.99, 127.55, 127.32, 127.31, 127.24, 127.10, 126.35, 125.85, 125.35, 115.86, 113.21, 54.72, 54.02, 53.82, 47.03, 42.17, 41.96, 37.51, 36.59, 23.99, 22.88, 21.31. HRMS: calcd. for $[\text{C}_{44}\text{H}_{47}\text{N}_3\text{O}_7\text{SH}]^+$ 762.32075, found 762.32139.

(Tyr(Me)-Phe-Leu-methyl-vinylsulfone)-2-(naphthalen-2-yl)-acetamide (IIb)

Following the general procedure for azide coupling the title compound was obtained from Boc-LeuVS (32 mg, 0.11 mmol, 1.1 equiv.) and (Tyr(Me)-Phe-hydrazinyl)-2-(naphthalen-2-yl)-acetamide (**10**, 52 mg, 0.1 mmol). Column chromatography (DCM \rightarrow 1.5% MeOH in DCM) gave the title compound as a white solid (36.2 mg, 53 μmol , 53%). ^1H NMR (400 MHz, CDCl_3): δ ppm 8.30 (d, $J = 8.0$ Hz, 1H), 8.24 (d, $J = 8.3$ Hz, 1H), 8.12 (d, $J = 8.3$ Hz, 1H), 7.85 (d, $J = 7.3$ Hz, 1H), 7.81–7.73 (m, 2H), 7.60 (s, 1H), 7.52–7.42 (m, 2H), 7.31–7.15 (m, 6H), 7.07 (d, $J = 8.1$ Hz, 2H), 6.68 (d, $J = 8.3$ Hz, 2H), 6.60 (dd, $J_1 = 15.2$, $J_2 = 4.9$ Hz, 1H), 6.32 (d, $J = 15.3$ Hz, 1H), 4.61–4.43 (m, 3H), 3.65 (s, 3H), 3.61 (d, $J = 13.9$ Hz, 1H), 3.49 (d, $J = 14.0$ Hz, 1H), 3.01 (dd, $J_1 = 13.5$, $J_2 = 6.6$ Hz, 1H), 2.95 (s, 3H), 2.91–2.82 (m, 2H), 2.66 (dd, $J_1 = 14.6$, $J_2 = 11.1$ Hz, 1H), 1.68–1.55 (m, 1H), 1.47–1.29 (m, 2H), 0.85 (dd, $J_1 = 15.5$, $J_2 = 6.5$ Hz, 6H). HRMS: calcd. for $[\text{C}_{39}\text{H}_{45}\text{N}_3\text{O}_6\text{SH}]^+$ 684.31018, found 684.31060.

(Tyr(Me)-Phe-Leu-epoxyketone)-2-(naphthalen-2-yl)-acetamide (IIc)

Following the general procedure for azide coupling the title compound was obtained from Boc-LeuEK (76 mg, 0.28 mmol, 1.1 equiv.) and (Tyr(Me)-Phe-hydrazinyl)-2-(naphthalen-2-yl)-acetamide (**10**, 0.13 g, 0.25 mmol). Column chromatography (DCM \rightarrow 2% MeOH in DCM) gave the title compound as a white solid (0.11 g, 0.17 mmol, 66%). ^1H NMR (400 MHz, CDCl_3): δ ppm 7.86–7.75 (m, 1H), 7.73–7.67 (m, 2H), 7.52 (s, 1H), 7.49–7.44 (m, 2H), 7.20–7.09 (m, 3H), 7.01–6.91 (m, 3H), 6.68 (d, $J = 8.6$ Hz, 2H), 6.57–6.47 (m, 1H), 6.40 (d, $J = 8.3$ Hz, 2H), 4.79–4.66 (m, 2H), 4.58 (dt, $J_1 = 19.8$, $J_2 = 3.0$ Hz, 1H), 3.65–3.45 (m, 5H), 3.24 (d, $J = 4.9$ Hz, 1H), 3.01–2.85 (m, 1H), 2.84–2.77 (m, 4H), 1.59–1.51 (m, 1H), 1.49 (s, 3H), 1.47–1.37 (m, 1H), 1.33–1.19 (m, 1H), 0.88 (dd, $J_1 = 13.1$, $J_2 = 6.4$ Hz, 6H). ^{13}C NMR (100 MHz, CDCl_3): δ ppm 207.99, 171.32, 170.57, 170.47, 158.50, 136.27, 133.56, 132.57, 131.70, 130.02, 129.36, 128.92, 128.87, 128.61, 128.56, 128.29, 128.25, 127.77, 127.72, 127.56, 127.12, 127.02, 126.98, 126.52, 126.19, 113.97, 79.36, 59.00, 55.11, 54.43, 54.01, 52.33, 50.11, 43.60, 39.94, 37.78, 36.31, 25.15, 23.30, 21.40, 16.71. HRMS: calcd. for $[\text{C}_{40}\text{H}_{45}\text{N}_3\text{O}_6\text{H}]^+$ 664.33811, found 664.33838.

Boc-Tyr(Me)-Phe-hydrazide (**11**)

Boc-Tyr(Me)-Phe-methyl ester (**8**, 1.17 g, 2.56 mmol) was dissolved in MeOH and hydrazine monohydrate (7.47 ml, 154 mmol, 60 equiv.) was added. The reaction mixture was refluxed for 2 h, before being concentrated until white precipitate is formed. The resulting suspension was cooled and the product was filtered off (1.03 g, 2.25 mmol, 88%). ^1H NMR (400 MHz, $\text{MeOD}-\text{CDCl}_3$): δ ppm 7.26–7.08 (m, 5H), 7.03 (d, $J = 8.6$ Hz, 2H), 6.79 (d, $J = 8.6$ Hz, 2H), 4.55–4.50 (m, 1H), 4.18 (t, $J = 6.6$ Hz, 1H), 3.01 (dd, $J_1 = 13.7$, $J_2 = 7.0$ Hz, 1H), 2.96–2.85 (m, 2H), 2.73 (dd, $J_1 = 13.5$, $J_2 = 8.1$ Hz, 1H), 1.34 (s, 9H). NMR (100 MHz, $\text{MeOD}-\text{CDCl}_3$): δ ppm 171.77, 170.37, 158.08, 135.87, 129.70, 128.62, 128.08, 127.96, 126.37, 113.40, 79.72, 55.67, 54.53, 52.52, 37.25, 36.74, 27.46.

Boc-Tyr(Me)-Phe-Leu-methyl-vinylsulfone (**12**)

Following the general procedure for azide coupling the title compound was obtained from Boc-LeuVS (0.24 g, 0.83 mmol, 1.1 equiv.) and Boc-Tyr(Me)-Phe-hydrazide (**11**, 0.39 g, 0.75 mmol). Purification by flash column chromatography (DCM \rightarrow 1.5% MeOH in DCM)

gave **12** (0.35 g, 0.56 mmol, 75%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.29–7.22 (m, 3H), 7.09 (d, *J* = 8.5 Hz, 2H), 7.03 (d, *J* = 6.1 Hz, 2H), 6.87 (d, *J* = 8.5 Hz, 2H), 6.82–6.65 (m, 2H), 6.47–6.37 (m, 2H), 4.84 (d, *J* = 3.0 Hz, 1H), 4.77–4.69 (m, 1H), 4.66 (dd, *J*₁ = 13.0, *J*₂ = 6.3 Hz, 1H), 4.16 (td, *J*₁ = 7.8, *J*₂ = 4.8 Hz, 1H), 3.80 (s, 3H), 3.32–3.23 (m, 1H), 3.03 (dd, *J*₁ = 14.3, *J*₂ = 5.0 Hz, 1H), 2.91 (s, 3H), 2.91–2.83 (m, 2H), 1.53–1.41 (m, 1H), 1.37–1.30 (m, 2H), 1.27 (s, 9H), 0.90 (d, *J* = 6.4 Hz, 3H), 0.86 (d, *J* = 6.5 Hz, 3H).

Azido-BODIPY-Tyr(Me)-Phe-Leu-methyl-vinylsulfone (**14**)

Boc-Tyr(Me)-Phe-LeuVS (**12**, 22 mg, 35 μmol) was dissolved in TFA–DCM 1: 1 (v/v). The reaction mixture was stirred for 30 min, before being co-evaporated with Tol. (3×). The crude TFA salt was dissolved in DCM and N₃-BODIPY-OSu17 (**13**, 20 mg, 35 μmol, 1 equiv.) and DiPEA (6 μl, 35 μmol, 1 equiv.) were added. The reaction mixture was stirred for 5 h, before being concentrated. Purification by flash column chromatography (DCM → 1.5% MeOH in DCM) afforded the title compound as a purple solid (18.2 mg, 18.9 μmol, 54%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.87 (d, *J* = 8.8 Hz, 2H), 7.29–7.20 (m, 3H), 7.07 (s, 1H), 7.04 (dd, *J*₁ = 7.4, *J*₂ = 1.5 Hz, 2H), 7.00–6.93 (m, 5H), 6.79 (d, *J* = 8.5 Hz, 2H), 6.71 (dd, *J*₁ = 15.1, *J*₂ = 4.6 Hz, 1H), 6.54 (d, *J* = 4.1 Hz, 1H), 6.52–6.44 (m, 2H), 6.21 (dd, *J*₁ = 15.1, *J*₂ = 1.1 Hz, 1H), 6.10–6.04 (m, 1H), 4.72–4.57 (m, 2H), 4.45 (q, *J* = 6.4 Hz, 1H), 4.10 (t, *J* = 5.9 Hz, 2H), 3.70 (s, 3H), 3.53 (t, *J* = 6.6 Hz, 3H), 3.19 (dd, *J*₁ = 13.8, *J*₂ = 5.4 Hz, 1H), 2.95–2.89 (m, 3H), 2.89 (s, 3H), 2.65–2.50 (m, 2H), 2.48 (s, 3H), 2.19–2.13 (m, 3H), 2.13 (s, 3H), 2.11–2.03 (m, 2H), 1.52–1.38 (m, 1H), 1.38–1.26 (m, 2H), 0.87 (t, *J* = 6.7 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.52, 170.81, 169.95, 159.55, 158.86, 158.32, 156.04, 147.21, 139.32, 135.87, 135.13, 134.04, 134.02, 130.77, 130.73, 130.69, 130.08, 129.60, 129.25, 129.21, 128.85, 128.80, 128.39, 127.41, 127.31, 125.53, 123.01, 118.64, 118.60, 118.58, 114.29, 114.20, 64.45, 55.19, 54.25, 48.20, 47.91, 42.74, 42.42, 37.17, 36.37, 35.82, 28.74, 24.61, 22.80, 21.74, 19.59, 13.09, 9.57. HRMS: calcd. for [C₅₀H₅₉BF₂N₈O₇SH]⁺ 965.43613, found 965.43837.

Boc-Tyr(Me)-Phe-Leu-epoxyketone (**15**)

Following the general procedure for azide coupling the title compound was obtained from Boc-LeuEK (0.22 g, 0.83 mmol, 1.1 equiv.) and Boc-Tyr(Me)-Phe-hydrazide (**11**, 0.39 g, 0.75 mmol). Purification by flash column chromatography (DCM → 1.5% MeOH in DCM) gave **15** (0.32 g, 0.54 mmol, 71%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.26–7.11 (m, 3H), 7.10–7.04 (m, 4H), 7.04–7.01 (m, 1H), 6.90 (s, 1H), 6.78 (d, *J* = 8.5 Hz, 2H), 5.31 (d, *J* = 7.7 Hz, 1H), 4.77 (q, *J* = 6.9 Hz, 1H), 4.56 (dt, *J*₁ = 9.8, *J*₂ = 3.2 Hz, 1H), 4.41 (s, 1H), 3.73 (s, 3H), 3.25 (d, *J* = 4.4 Hz, 1H), 3.02 (dd, *J*₁ = 14.0, *J*₂ = 6.8 Hz, 1H), 2.98–2.88 (m, 3H), 2.84 (d, *J* = 4.9 Hz, 1H), 1.58–1.51 (m, 1H), 1.49 (s, 3H), 1.48–1.38 (m, 1H), 1.36 (s, 9H), 1.27–1.18 (m, 1H), 0.88 (dd, *J*₁ = 12.3, *J*₂ = 6.4 Hz, 6H).

Azido-BODIPY-Tyr(Me)-Phe-Leu-epoxyketone (**16**)

Boc-Tyr(Me)-Phe-LeuEK (**15**, 21 mg, 35 μmol) was dissolved in TFA–DCM 1: 1 (v/v). The reaction mixture was stirred for 30 min, before being co-evaporated with Tol. (3×). The crude TFA salt was dissolved in DCM and N₃-BODIPY-OSu17 (**13**, 20 mg, 35 μmol, 1 equiv.) and DiPEA (6 μl, 35 μmol, 1 equiv.) were added. The reaction mixture was stirred for 15 h, before being concentrated. Purification by flash column chromatography (DCM → 1% MeOH in DCM) afforded the title compound as a purple solid (8.8 mg, 9.3 μmol, 27%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.87 (d, *J* = 8.6 Hz, 2H), 7.27–7.19 (m, 3H), 7.11–7.05 (m, 3H), 7.00–6.92 (m, 5H), 6.76 (d, *J* = 8.2 Hz, 2H), 6.54 (d, *J* = 3.9 Hz, 1H), 6.32 (d, *J* = 7.6 Hz, 1H), 6.03 (d, *J* = 7.6 Hz, 1H), 5.88 (d, *J* = 7.0 Hz, 1H), 4.58–4.47 (m, 3H), 4.10 (t, *J* = 5.8 Hz, 2H), 3.73–3.70 (m, 3H), 3.53 (t, *J* = 6.6 Hz, 2H), 3.23 (d, *J* = 4.8 Hz, 1H), 3.08–2.89 (m, 4H), 2.88 (d, *J* = 4.8 Hz, 1H), 2.76–2.55 (m, 2H), 2.51 (s, 3H), 2.33–2.20 (m, 2H), 2.18 (s, 3H), 2.08 (td, *J*₁ = 12.1, *J*₂ = 6.1 Hz, 2H), 1.50 (s, 3H), 1.49–1.38 (m,

2H), 1.20–1.13 (m, 1H), 0.89 (dd, $J_1 = 13.7$, $J_2 = 5.5$ Hz, 6H). HRMS: calcd. for $[C_{51}H_{59}BF_2N_8O_7H]^+$ 945.46406, found 945.46639.

Az-Ala-Pro-Nle-OMe (19)

Resin-bound Fmoc-Ala-Pro-Nle (synthesis described above, 0.25 mmol) was deprotected with piperidine–NMP (1: 4, v/v, 20 min), washed with NMP (3 \times) and DCM (3 \times), and capped with azido acetic acid (63 mg, 0.63 mmol, 2.5 equiv.) under the influence of BOP (0.28 g, 0.63 mmol, 2.5 equiv.) and DiPEA (0.12 ml, 0.75 mmol, 3 equiv.) for 15 h. Mild acidic cleavage of resin **17** with 1% TFA in DCM (3 \times 10 min.) and co-evaporation with Tol. (3 \times) resulted in the crude Az-Ala-Pro-NLe-OH **18** which was used without purification. The crude peptide was dissolved in MeOH–Tol. (1: 1) and treated with TMS–diazomethane (0.25 ml 2 M in hexanes, 0.5 mmol, 2 equiv.) for 15 min before being co-evaporated with Tol. (3 \times). Purification by flash column chromatography (DCM \rightarrow 2.5% MeOH in DCM) yielded the title compound as a white solid (89.3 mg, 0.23 mmol, 90%). 1H NMR (400 MHz, $CDCl_3$): δ ppm 7.25 (d, $J = 7.4$ Hz, 1H), 7.11 (d, $J = 7.7$ Hz, 1H), 4.77 (p, $J = 7.0$ Hz, 1H), 4.62 (dd, $J_1 = 8.1$, $J_2 = 2.6$ Hz, 1H), 4.50 (dt, $J_1 = 7.7$, $J_2 = 5.5$ Hz, 1H), 3.98 (d, $J = 3.6$ Hz, 2H), 3.74 (s, 3H), 3.70–3.55 (m, 2H), 2.39–2.29 (m, 1H), 2.23–2.08 (m, 1H), 2.08–1.99 (m, 1H), 1.98–1.89 (m, 1H), 1.87–1.76 (m, 1H), 1.71–1.59 (m, 1H), 1.40 (d, $J = 6.9$ Hz, 3H), 1.35–1.21 (m, 2H), 0.88 (t, $J = 7.0$ Hz, 3H).

Az-Ala-Pro-Nle-hydrazide (20)

Az-Ala-Pro-NLe-OMe (**19**, 89.3 mg, 0.23 mmol) was dissolved in MeOH. Hydrazine monohydrate (0.67 ml, 13.8 mmol, 60 equiv.) was added and the reaction mixture was refluxed for 2 h. Tol. was added and the resulting white solid was filtered to give the title compound (90 mg, 0.23 mmol, quant.). 1H NMR (400 MHz, MeOD): δ ppm 4.65 (q, $J = 7.0$ Hz, 1H), 4.46 (dd, $J_1 = 8.2$, $J_2 = 4.6$ Hz, 1H), 4.23 (dd, $J_1 = 8.4$, $J_2 = 6.0$ Hz, 1H), 3.89 (s, 2H), 3.86–3.77 (m, 1H), 3.70–3.60 (m, 1H), 2.30–2.12 (m, 1H), 2.12–1.91 (m, 2H), 1.83–1.72 (m, 1H), 1.71–1.61 (m, 1H), 1.44–1.25 (m, 7H), 0.92 (t, $J = 6.9$ Hz, 3H).

Az-Ala-Pro-NLe-Leu-epoxyketone (21)

Following the general procedure for azide coupling the title compound was obtained from Boc-LeuEK (38.8 mg, 0.14 mmol, 1.1 equiv.) and Az-Ala-Pro-Nle-hydrazide (**19**, 53.2 mg, 0.13 mmol). Purification by flash column chromatography (DCM \rightarrow 2% MeOH in DCM) gave **21** (15.9 mg, 30 μ mol, 23%). 1H NMR (400 MHz, $CDCl_3$): δ ppm 7.16 (d, $J = 7.4$ Hz, 1H), 7.08 (d, $J = 7.7$ Hz, 1H), 6.40 (d, $J = 8.0$ Hz, 1H), 4.77 (p, $J = 6.9$ Hz, 1H), 4.62–4.54 (m, 2H), 4.30 (dt, $J_1 = 7.8$, $J_2 = 5.7$ Hz, 1H), 3.98 (d, $J = 5.0$ Hz, 2H), 3.71–3.62 (m, 1H), 3.61–3.55 (m, 1H), 3.31 (d, $J = 5.0$ Hz, 1H), 2.89 (d, $J = 5.0$ Hz, 1H), 2.35–2.27 (m, 1H), 2.20–2.09 (m, 1H), 2.07–1.99 (m, 1H), 1.98–1.90 (m, 1H), 1.85–1.75 (m, 1H), 1.69–1.53 (m, 2H), 1.51 (s, 3H), 1.39 (d, $J = 6.8$ Hz, 3H), 1.36–1.20 (m, 6H), 0.94 (dd, $J_1 = 6.5$, $J_2 = 2.4$ Hz, 6H), 0.88 (t, $J = 7.1$ Hz, 3H). HRMS: calcd. for $[C_{25}H_{41}N_7O_6H]^+$ 536.31911, found 536.31980.

Green fluorescent β 1 specific probe (23)

β 1 selective probe **21** (7.7 mg, 0.014 mmol) was reacted with acetylene-functionalised BODIPY **2218** (4.7 mg, 0.014 mmol, 1.0 equiv.) catalysed by $CuSO_4$ (0.05 ml 28 mM in H_2O , 1.4 μ mol, 10 mol%) and sodium ascorbate (0.05 ml 44 mM in H_2O , 2.2 μ mol, 15 mol%) in a mixture of Tol.– H_2O –*t*BuOH (final ratio 1: 1: 1, v/v/v, 0.6 ml) at 80 $^\circ C$ for 22 h. The mixture was then allowed to cool to room temperature and concentrated *in vacuo*. Purification by column chromatography (DCM \rightarrow 2% MeOH in DCM) gave the fluorescent probe **23** (8.6 mg, 9.3 μ mol, 65%) as an orange solid. 1H NMR (400 MHz, DMSO): δ ppm 8.66 (d, $J = 6.8$ Hz, 1H), 8.09 (d, $J = 7.2$ Hz, 1H), 7.80–7.77 (m, 2H), 6.23 (s, 2H), 5.07 (s,

2H), 4.56–4.53 (s, 1H), 4.38–4.33 (m, 2H), 4.24–4.17 (m, 1H), 3.58–3.55 (m, 2H), 3.19–3.17 (m, 1H), 3.02–2.96 (m, 3H), 2.72 (t, $J = 7.2, 7.2$ Hz), 2.41 (s, 6H), 2.40 (s, 6H), 1.98–1.94 (m, 2H), 1.89–1.81 (m, 4H), 1.64–1.62 (m, 4H), 1.47–1.44 (m, 1H), 1.41 (s, 3H), 1.36–1.31 (m, 2H), 1.24–1.20 (m, 7H), 0.91 (d, $J = 6.8$ Hz, 6H), 0.88–0.81 (m, 3H). ^{13}C NMR (100 MHz, DMSO): δ ppm 208.28, 171.87, 170.92, 170.39, 165.03, 153.06, 146.68, 140.90, 130.72, 123.50, 121.69, 59.18, 58.93, 51.99, 51.64, 51.22, 49.60, 46.70, 46.41, 38.33, 31.90, 30.81, 29.43, 28.78, 27.61, 27.20, 24.53, 24.40, 23.16, 21.92, 20.98, 17.07, 16.52, 15.83, 14.08, 13.92. HRMS: calcd. for $[\text{C}_{44}\text{H}_{64}\text{BF}_2\text{N}_9\text{O}_6\text{H}]^+$ 864.51134, found 864.51332.

Competition and labeling experiments *in vitro*

HEK293T cells were cultured on DMEM supplemented with 10% Fetal Calf Serum (FCS), 10 units ml^{-1} penicillin and 10 $\mu\text{g ml}^{-1}$ streptomycin in a 7% CO_2 humidified incubator at 37 °C. Cells were harvested, washed with PBS (2 \times) and permeated in digitonin lysis buffer (4 \times pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose, 5 mM MgCl_2 , 5 mM DTT, 0.025% digitonin) for 5 min on ice and centrifuged at 16,100 rcf for 20 min at 4 °C. The supernatant containing the cytosolic fraction was collected and the protein content was determined by Bradford assay. 10 μg total protein per experiment was exposed to the inhibitors or fluorescent probes (10 \times solution in DMSO) for 1 h at 37 °C prior to incubation with MV151 (1 μM) for 1 h at 37 °C in case of a competition experiment. Reaction mixtures were boiled with Laemmli's buffer containing β -mercapto-ethanol for 3 min before being resolved on 12.5% SDS-PAGE. In-gel detection of fluorescently labeled proteins was performed in the wet gel slabs directly on the Typhoon Variable Mode Imager (Amersham Biosciences) using the Cy3/Tamra settings (λ_{ex} 532, λ_{em} 560) for MV151 and the azido-BODIPY functionalized probes **14**, **16** and **25** or λ_{ex} 488 nm, λ_{em} 520 nm for probes **23** and **24**.

Competition and labeling experiments in living cells

HEK293T cells were cultured on DMEM supplemented with 10% Fetal Calf Serum (FCS), 10 units ml^{-1} penicillin and 10 $\mu\text{g ml}^{-1}$ streptomycin in a 7% CO_2 humidified incubator at 37 °C. Some 5×10^5 HEK293T cells were seeded in 6 cm Petri dishes and allowed to grow O/N in 2 ml of medium. The cells were exposed to the indicated concentrations of the inhibitors or fluorescent probes (100 \times solution in DMSO) for 2 h, before being washed with PBS (2 \times) and harvested. The cells were permeated in digitonin lysis buffer (4 \times pellet volume, 50 mM Tris pH 7.5, 250 mM sucrose, 5 mM MgCl_2 , 5 mM DTT, 0.025% digitonin) for 5 min on ice and centrifuged at 16,100 rcf for 20 min at 4 °C. The supernatant containing the cytosolic fraction was collected and the protein content was determined by Bradford assay. In case of a competition experiment, the lysates were exposed to MV151 (1 μM) for 1 h at 37 °C. Some 10 μg protein/lane was boiled for 5 min in Laemmli's sample buffer containing beta-mercapto-ethanol and the proteins were resolved by 12.5% SDS-PAGE. Labeled proteasome subunits were visualised by in-gel fluorescence scanning on a Typhoon variable mode imager (Amersham Biosciences) using the Cy3/Tamra settings (λ_{ex} 532, λ_{em} 560) for MV151 and the azido-BODIPY functionalized probes **14**, **16** and **25** or λ_{ex} 488 nm, λ_{em} 520 nm for probes **23** and **24**.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by The Netherlands Organization for Scientific Research (NWO), The Netherlands Genomics Centre Initiative (NGI) and the NCI (grant RO1CA124634). We thank Hans van den Elst and Nico Meeuwenoord for HPLC and LC-MS assistance.

References and notes

1. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, Colbert RA. *J Exp Med.* 1998; 187:97–104. [PubMed: 9419215]
2. Murata S, Sasaki K, Kishimoto T, Niwa S, Hayashi H, Takahama Y, Tanaka K. *Science.* 2007; 316:1349–1353. [PubMed: 17540904]
3. (a) Arendt CS, Hochstrasser M. *Proc Natl Acad Sci U S A.* 1997; 94:7156–7161. [PubMed: 9207060] (b) Chen P, Hochstrasser M. *Cell.* 1996; 86:961–972. [PubMed: 8808631] (c) Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. *J Biol Chem.* 1997; 272:25200–25209. [PubMed: 9312134]
4. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. *Bioorg Med Chem Lett.* 1998; 8:333–338. [PubMed: 9871680]
5. (a) Kane RC, Bross PF, Farrell AT, Pazdur R. *Oncologist.* 2003; 8:508–513. [PubMed: 14657528] (b) Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME, Bradley S, Gobburu JV, Goheer A, Lee SL, Leighton J, Liang CY, Lostritto RT, McGuinn WD, Morse DE, Rahman A, Rosario LA, Verbois SL, Williams G, Wang YC, Pazdur R. *Clin Cancer Res.* 2004; 10:3954–3964. [PubMed: 15217925] (c) Adams J. *Nat Rev Cancer.* 2004; 4:349–360. [PubMed: 15122206] (d) Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al. *N Engl J Med.* 2005; 352:2487–2498. [PubMed: 15958804]
6. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R. *Clin Cancer Res.* 2007; 13:5291–5294. [PubMed: 17875757]
7. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galaray PJ. *Nat Methods.* 2005; 2:357–362. [PubMed: 15846363]
8. (a) Altun M, Galaray PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM. *Cancer Res.* 2005; 65:7896–7901. [PubMed: 16140960] (b) Kisselev AF, Callard A, Goldberg AL. *J Biol Chem.* 2006; 281:8582–8590. [PubMed: 16455650]
9. Britton M, Lucas MM, Downey SL, Screen M, Pletnev AA, Verdoes M, Tokhunts R, Amir O, Goddard A, Pelphrey P, Wright DL, Overkleeft HS, Kisselev AF. *Chem Biol.* 2009; 16:1278–1289. [PubMed: 20064438]
10. For a recent review see: Verdoes M, Florea BI, Van der Marel GA, Overkleeft HS. *Eur J Org Chem.* 2009:3301–3313.
11. Verdoes M, Florea BI, Van Der Linden WA, Renou D, Van Den Nieuwendijk AM, Van Der Marel GA, Overkleeft HS. *Org Biomol Chem.* 2007; 5:1416–1426. [PubMed: 17464411]
12. Bogyo M, Shin S, McMaster JS, Ploegh HL. *Chem Biol.* 1998; 5:307–320. [PubMed: 9653549]
13. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh HL. *Proc Natl Acad Sci U S A.* 1997; 94:6629–6634. [PubMed: 9192616]
14. Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BH, Crews CM. *Bioorg Med Chem Lett.* 1999; 9:2283–2288. [PubMed: 10465562]
15. Verdoes M, Florea BI, Menendez-Benito V, Maynard CJ, Witte MD, Van Der Linden WA, Van Den Nieuwendijk AMCH, Hofmann T, Berkers CR, van Leeuwen FW, Groothuis TA, Leeuwenburgh MA, Ovaa H, Neefjes JJ, Filippov DV, Van Der Marel GA, Dantuma NP, Overkleeft HS. *Chem Biol.* 2006; 13:1217–1226. [PubMed: 17114003]
16. van Swieten PF, Samuel E, Hernández RO, Van Den Nieuwendijk AM, Leeuwenburgh MA, Van Der Marel GA, Kessler BM, Overkleeft HS, Kisselev AF. *Bioorg Med Chem Lett.* 2007; 17:3402–3405. [PubMed: 17442566]
17. Verdoes M, Florea BI, Hillaert U, Willems LI, Van Der Linden WA, Sae-Heng M, Filippov DV, Kisselev AF, Van Der Marel GA, Overkleeft HS. *ChemBioChem.* 2008; 9:1735–1738. [PubMed: 18600815]
18. Verdoes M, Hillaert U, Florea BI, Sae-Heng M, Risseeuw MD, Filippov DV, Van Der Marel GA, Overkleeft HS. *Bioorg Med Chem Lett.* 2007; 17:6169–6171. [PubMed: 17888658]
19. Florea BI, Verdoes M, Li N, Van der Linden WA, Geurink PP, Van den Elst H, Hofmann T, de Ru A, Van Veelen P, Tanaka K, Sasaki K, Murata S, Den Dulk H, Brouwer J, Ossendorp F, Overkleeft HS. manuscript submitted for publication.




Fig. 1.
(A) Schematic representation of the eukaryotic 20S proteasome and previously described β 1 and β 5 specific proteasome inhibitors. The proteolytically active β subunits are marked in red. **(B)** Recognition elements I and II and warheads a–c resulting in 6 hybrid structures, **Ia–c** and **IIa–c**.




Fig. 2. Proteasome profiling screen of the hybrids **Ia–c** and **IIa–c** using MV151. **(A)** HEK293T lysates (10 μg total protein) were incubated with the indicated concentrations of compounds **Ia–c** and **IIa–c** for 1 h at 37 $^{\circ}\text{C}$. The residual proteasome activity was fluorescently labeled by incubation with 1 μM MV151 for 1 h at 37 $^{\circ}\text{C}$. **(B–C)** The fluorescent band intensity for each subunit was quantified to give competition curves as shown in **(B)** for **IIb** and in **(C)** for **IIc**.




Fig. 3.

Labeling profile of probe **14**, **16** and **23**. **(A)** HEK293T lysates (10 μ g total protein) were incubated with the indicated concentrations of **23**, **24** (left panel), **14** (middle panel) or **16** (right panel) for 1 h at 37 $^{\circ}$ C. **(B)** HEK293T cells (some 5×10^5 cells) were exposed to the indicated concentrations of **23** or **24** (left panel), **14** or **25** (middle panel) or **16** (right panel) for 2 h at 37 $^{\circ}$ C. **(C)** Quantification of fluorescent labeling of living cells treated with **23** (left panel), **14** (middle panel) and **16** (right panel). Corresponding gels are shown in Fig. 3B. **(D)** Structures of reference probes **24** and **25**.







Fig. 4. Labeling and, hence, chemical knock-down of specific proteasome active sites. HEK293T lysates (10 μ g total protein) were incubated with the indicated concentrations of probes for 1 h at 37 °C. Merged image of fluorescence scanned at λ_{ex} 488, λ_{em} 520 nm in green and λ_{ex} 532, λ_{em} 560 nm in red.

**Scheme 1.**

Synthesis of the hybrid structures. **Reagents and conditions:** (i) 1% TFA in DCM, 30 min, 3 \times . (ii) TMS-diazomethane (2 equiv.), 15 min., 85% from Fmoc-Nle-resin. (iii) Hydrazine monohydrate (60 equiv.), MeOH, reflux, 1.5 h, 92%. (iv) (a) HCl (2.8 equiv.), *t*BuONO (1.1 equiv.), DMF-EtOAc (1: 1, v/v), -25 $^{\circ}$ C, 4 h. (b) TFA-H-R^{a-c} (1.1 equiv.), DiPEA (3.8 equiv.), -25 $^{\circ}$ C to RT, 15 h, **Ia** 77%, **Ib** 34%, **Ic** 63%, **Ila** 77%, **Ilb** 53%, **Ilc** 66%. (v) HCl-H-Phe-OMe (1 equiv.), BOP (1 equiv.), DiPEA (2.2 equiv.), DCM, 15 h, quant. (vi) TFA/DCM 1: 1 (v/v), 15 min. (vii) 2-(Naphthalen-2-yl)-acetic acid (1 equiv.), BOP (1 equiv.), DiPEA (3.3 equiv.), DCM, 15 h, 68%. (viii) Hydrazine monohydrate (60 equiv.), MeOH, reflux, 2.5 h, 95%.

**Scheme 2.**

Synthesis of azido-BODIPY probes **14** and **16**. **Reagents and conditions:** (i) Hydrazine monohydrate (60 equiv.), MeOH, reflux, 2 h, 88%. (ii) (a) HCl (2.8 equiv.), *t*BuONO (1.1 equiv.), DMF–EtOAc (1: 1, v/v), –25 °C, 4 h. (b) TFA·H-LeuVS (1.1 equiv.), DiPEA (3.8 equiv.), –25 °C to RT, 15 h, 75%. (iii) TFA/DCM 1: 1 (v/v), 30 min. (iv) **13** (1 equiv.), DiPEA (1 equiv.), DCM, 15 h, **14** 54%, **16** 27%. (v) (a) HCl (2.8 equiv.), *t*BuONO (1.1 equiv.), DMF–EtOAc (1: 1, v/v), –25 °C, 4 h. (b) TFA·H-LeuEK (1.1 equiv.), DiPEA (3.8 equiv.), –25 °C to RT, 15 h, 71%.

**Scheme 3.**

Synthesis of the fluorescent $\beta 1$ selective proteasome probe **23**. **Reagents and conditions:** (i) 1% TFA in DCM, 30 min, 3 \times . (ii) TMS-diazomethane (2 equiv.), 15 min, 90% from Fmoc-Nle-resin. (iii) Hydrazine monohydrate (60 equiv.), MeOH, reflux, 1.5 h, quant. (iv) (a) HCl (2.8 equiv.), *t*BuONO (1.1 equiv.), DMF-EtOAc (1: 1, v/v), -25 °C, 4 h. (b) TFA-H-Leu-epoxyketone (1.1 equiv.), DiPEA (3.8 equiv.), -25 °C to RT, 15 h, 23%. (v) **22**, CuSO₄ (10 mol%), sodium ascorbate (15 mol%), Tol.-H₂O-*t*BuOH (1: 1: 1, v/v/v), 80 °C, 22 h, 65%.

Table 1Apparent IC₅₀ values (μM) for **Ia–c** and **IIa–c**^a

| Subunit | β1 | β2 | β5 |
|------------|-------------|-------------|---------------|
| Compound | | | |
| Ia | 4.0 ± 0.67 | >100 | >100 |
| Ib | 7.8 ± 0.86 | >100 | >100 |
| Ic | 0.66 ± 0.12 | >100 | 373 ± 91 |
| IIa | 32 ± 16 | 78 ± 23 | 0.07 ± 0.01 |
| IIb | >100 | >100 | 0.11 ± 0.02 |
| IIc | >100 | 0.28 ± 0.04 | 0.013 ± 0.001 |

^aIn the gels shown in Fig. 2, the fluorescent band intensity for each subunit was quantified in each lane to give competition curves, which were then used to calculate apparent IC₅₀ values. IC₅₀ values for irreversible inhibitors do not refer to inhibition constants (IC₅₀ ≠ K_i). It is the observed 1/2 max inhibition concentration for the specific experimental setup.